Home > Boards > US OTC > Cannabis > Fusion Pharm, Inc. (FSPM)

Let me get this straight. Two lawyers rendered

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
HopScotch2 Member Profile
Member Level 
Followed By 27
Posts 1,579
Boards Moderated 0
Alias Born 05/17/15
160x600 placeholder
HopScotch2 Member Level  Friday, 04/21/17 06:13:35 PM
Re: HopScotch2 post# 9432
Post # of 9491 
Let me get this straight. Two lawyers rendered opinions that opine that the shares subject to the opinions can be publicly sold in reliance upon Rule 144 as Fusion Pharm has never been a shell company. A 2 minute review of Fusion Pharm’s shell status shows that it was a former shell company and Rule 144 was not available.

According to the SEC, Rule 144 is not available for the resale of securities initially issued by a shell company (reporting or non-reporting) or a former shell company. Rule 405 and Exchange Act Rule 12b-2 define a “shell company” as a company, other than an asset-backed issuer, with no or nominal operations; and either no or nominal a no brainer to confirm shell status from Fusion Pharm’s public filings.

The OTC Markets profile page for Fusion Pharm states its corporate history:

Company History:

• Formerly=Baby Bee Bright Corp. until 4-2011
• Formerly=Sequoia Interests Corp. until 5-06
• Note=1-04 company is in the development stage, working with a nationally recognized, independent research and development organization to develop and test an inorganic polymer designed to assist in the recovery of reserves in the oil & gas industry
• Formerly=Argent Capital Corp. until 12-03
• Formerly=Sunport Medical Corp. until 2-98

A review of the filings for Fusion Pharm’s reveals that it was a shell company. The first filing I reviewed for Argent Capital Corp, states, “On June 26, 2000 Argent Capital Corporation and its various subsidiaries ceased operating due to the company's inability to fund its business plan”. The same filing reflects all officers and directors had resigned and it had nominal assets.
As such, every opinion rendered under Rule 144 was baseless. SEC Attorneys Kimberly Greer and Ian Karpel failed to properly investigate this matter. Had they done so, all attorneys would have been charged. They either ignored that one of their own rendered baseless opinions and violated the securities laws or they are completely incompetent and wasted tax payer dollars.

Talk about corruption - It is time to investigate the AUSA in FSPM Kenneth Harmon and the SEC attorneys who ignored and or took affirmative steps to conceal the role of a former SEC enforcement lawyer who worked with Harmon at the Miami DOJ.

The Big Apple connections are interesting particularly Guy Jean-Pierre. Isn't corruption the new agenda for the DOJ? FSPM is a good place to start the investigation of the FBI/DOJ Microcap Task Force (Also known as the penny stock key stone cops) and the complete abuse of their positions on tax payer dollars by a few involved who used their positions to target ex-wives and people they did not like.

Corruption and Waste doesn't get any clearer than that. And so they should he held to the same standard as anyone else - obstruction of justice and fraud. They belong behind bars.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist